$NBIO Nascent CEO, Sean Carrick, commented: "We couldn't be more excited to work with HypoSpray's team and its leading delivery system technology. This collaboration has the potential to drive tangible breakthroughs in cancer treatment and patient care that enable home administration, eventually eliminating the need for bi-weekly multi-hour visits to the infusion center, materially improving quality of life for patients undergoing treatment."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.